GO:0038166 angiotensin-activated signaling pathway

The angiotensin-activated signaling pathway (GO:0038166) is a biological process defined as a G protein-coupled receptor signaling pathway initiated by angiotensin II binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. This pathway is central to the renin-angiotensin system, which controls blood pressure, fluid homeostasis, and vascular tone. Because angiotensin II is a potent vasoactive peptide, dysregulation of its signaling contributes to hypertension, heart failure, and kidney disease. Understanding the molecular steps of this pathway is therefore essential for both basic vascular biology and therapeutic development. At the cellular level, angiotensin II engages G protein-coupled receptors, most notably AGTR1, to trigger intracellular calcium mobilization and contraction in vascular smooth muscle cells. This calcium-driven contraction pathway is a well-characterized downstream output of angiotensin-activated signaling and can be inhibited by natural compounds such as trifolin. The pathway also regulates gene transcription, cell growth, and extracellular matrix production, linking acute vasoconstriction to long-term vascular remodeling. For researchers, GO:0038166 provides a standardized framework to annotate genes and processes involved in angiotensin II responses. It enables comparative analysis across cell types and disease models, and supports the design of CRISPR-based experiments to test causality of candidate genes. This article summarizes the definition, mechanism, key genes, disease relevance, and research methods for GO:0038166, with all factual claims supported by published literature.

GO:0038166, angiotensin-activated signaling pathway, is defined as a G protein-coupled receptor signaling pathway initiated by angiotensin II binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. In other words, it is the entire sequence of molecular events that converts an extracellular angiotensin II signal into a functional cellular response, such as contraction, secretion, or changes in gene expression.

GO:0038166 is important because it formalizes the molecular logic of angiotensin II action, a central axis in cardiovascular and renal physiology. Dysregulation of this pathway is a driver of hypertension, heart failure, and chronic kidney disease, and it contributes to vascular remodeling and fibrosis. The pathway also intersects with cancer biology and metabolic disorders, making it a broad research priority. Because angiotensin II signaling culminates in calcium-driven contraction in vascular smooth muscle, it provides a measurable physiological endpoint for genetic and pharmacological studies. CRISPR-based models of genes in this pathway allow researchers to move from correlation to causation, identifying which components are required for specific angiotensin II responses.

The following genes and proteins are core components or well-characterized modulators of the angiotensin-activated signaling pathway (GO:0038166), based on published literature.

The angiotensin-activated signaling pathway is regulated at multiple levels, including ligand availability, receptor density and desensitization, G protein coupling efficiency, and second messenger degradation. Beta-arrestins (ARRB1, ARRB2) promote receptor desensitization and internalization, providing a key negative feedback mechanism. Calcium signals are terminated by pumps and exchangers that restore low cytosolic calcium, and by phosphatases that reverse phosphorylation events. Pharmacological modulation, such as inhibition of calcium-driven contraction by trifolin, demonstrates that the pathway can be dampened at the effector level. These regulatory nodes are attractive targets for CRISPR-based perturbation to test their contribution to pathway output.

Overactivation of angiotensin-activated signaling is a major driver of hypertension through vasoconstriction and sodium retention. The pathway also promotes cardiac hypertrophy and vascular remodeling, contributing to heart failure and atherosclerosis. Targeting AGTR1 and downstream calcium-contraction effectors is a validated therapeutic strategy, and CRISPR models can identify which components are required for pathological remodeling.

Angiotensin II signaling contributes to glomerular hypertension, proteinuria, and renal fibrosis. The pathway regulates transcription of profibrotic genes in mesangial and tubular cells, linking acute signaling to chronic structural damage. Knockout and knock-in models of AGTR1 and downstream transcription factors can clarify causal roles in kidney disease progression.

Angiotensin II signaling has been implicated in tumor angiogenesis, proliferation, and extracellular matrix remodeling in several cancers. The pathway can influence both cancer cells and stromal cells, including vascular smooth muscle and pericytes. CRISPR screens targeting pathway genes can reveal context-dependent oncogenic or tumor-suppressive roles.

Calcium imaging with fluorescent indicators measures the second messenger surge that follows angiotensin II receptor activation. Contractility assays in vascular smooth muscle cells quantify the physiological output of the calcium-driven contraction pathway. These methods are used to test whether CRISPR perturbations of AGTR1, PLCB1, or MYLK alter pathway function.

Luciferase or fluorescent reporters driven by angiotensin II-responsive promoters measure the transcriptional arm of GO:0038166. Reporter knock-in cell lines allow real-time monitoring of pathway activation in live cells. These assays are useful for screening compounds such as trifolin that modulate the pathway.

Pooled CRISPR knockout screens can identify genes required for angiotensin II-induced calcium flux or transcription. Hit validation uses individual knockout clones and rescue experiments. This approach is powerful for discovering novel modulators of the pathway beyond known components.

Western blotting for phosphorylated myosin light chain, ERK, or PKC substrates measures pathway activation. GTP-loading assays and IP3 measurements provide direct readouts of G protein and phospholipase C activity. These methods complement genetic perturbations by defining the molecular step affected.

Researchers studying angiotensin-activated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in angiotensin II responses, rather than merely correlated with them. EDITGENE provides publication-ready CRISPR cell models and screening services to test causality across the pathway, from receptor binding to transcriptional output.

GO:0038166, the angiotensin-activated signaling pathway, is a central biological process that converts angiotensin II binding into calcium-driven contraction and transcriptional regulation. Its dysregulation underlies major cardiovascular and renal diseases, and it is a validated therapeutic target. CRISPR-based models are powerful tools for dissecting the causal roles of AGTR1, downstream G proteins, calcium effectors, and feedback regulators. By combining genetic perturbation with functional assays, researchers can advance both mechanistic understanding and drug discovery for this pathway.